Innovative solutions
    for more effective diagnostics

Presentation

Products

Pathogens

Client Care

Science

IFU

Contact

Blog

Last news

TRAPIST, a new diagnostic system

TRAPIST V6

Coris BioConcept has always been committed to developing new technologies and products so its customers can perform more rapidly and accurately the detection and identification of infectious agents.

For more than 6 years, Coris has set up throughout two european projects a new R&D diagnostic platform called TRAPIST : The Rapid Advanced PCR & Immunoassay SysTem.

TRAPIST V6 is a fully automated instrument that performs multiplex diagnostic testings.
It is intended to be used in clinical laboratories for fast and easy multiplex diagnostics with disposable microfluidic chips.
Results are available within an hour. The platform enables a wide range of molecular assays as well as immunoassays.

 Img_Blog_Trapist_Machine_cercle          Img_Blog_Trapist_Puce_cercle

Coris BioConcept’s lab-on-a-chip is a disposable device that combines multiplex PCR amplification and detection by hybridization on a membrane in a microfluidic environment.
Used in conjunction with the Trapist V6 automated system, the disposable microfluidic chip supports all the steps of a rapid, specific and sensitive multiplex diagnostic from a single DNA sample preparation.
DNA sample and reagents are introduced into the chip by a simple and convenient procedure before being automatically processed by the Trapist V6 system.
The entire chip is airtight, preventing carry-over contamination with amplified DNA.

Want to discover how it works ?

Contact us for more information

Coris BioConcept at MEDICA Trade Fair 2015

 

 

Medica Trade Fair 2015

As every year Coris BioConcept will be exhibiting at MEDICA Trade Fair 2015 in Düsseldorf (Germany) from 16 to 19 November.

MEDICA is the world‘s largest medical marketplace annually organized in Europe. Attending MEDICA Trade Fair means having new opportunities to meet experts from the diagnostic field and to start new professional partnerships.

You will have the opportunity to discover our totally new product caller TRAPIST which is a new diagnostic platform that combines microfluidic and multiplex technologies.

Meet Coris BioConcept

Coris BioConcept is a middle-sized company (SME) specialized in developing, manufacturing and marketing rapid diagnostic tests (see our products).

For more than 15 years we provide rapid diagnostic products with high quality, easy to use and accessible everywhere to everybody. Our vision is to be innovative and global market leader in in vitro diagnostic in a sustainable economy that respects the environment and the person!

So, we gladly invite you to meet us at our booth 1F38 from November 16 to 19 !

Coris BioConcept Booth

Dr Thierry LECLIPTEUX (CEO & CSO) or Dr Christel BOUDRY (Product specialist & Business developer) will be pleased to meet you there.

appointmentbuttonV2

Please do not hesitate to Contact us for any other information.

Best regards,

Coris BioConcept Team

Chips4Life Final Workshop


The final workshop of the EC-funded FP7 project Chips4Life will take place from 9am-6pm on the 29th of June 2015 at the CHU de Liège, Belgium.

C4L-LOGO

Chips4Life aimed to develop a multiplex diagnostic test that will help clinicians to rapidly establish the agents responsible for a respiratory pathology in patients.

Don’t hesitate to participate and register now for this Chips4Life worship !

C4L-REGISTER

You can contact us for more details, or directly download the workshop’s programme.

Carbapenemase-Producing Enterobacteriaceae (CPE)


Coris BioConcept
 has always been committed to developing new technologies and products so its customers can perform more rapidly and accurately the detection and identification of infectious agents.

To face the growing problem of antibiotic-resistant bacteria, we have developed a new family of tests under the brand name “RESIST”.

LOGO-RESIST-R•G-WBg

Carbapenemase-Producing Enterobacteriaceae (CPE) represent a major health concern and any diagnostic tool allowing to help their laboratory detection can improve patient’s safety. Until today, non-molecular confirmatory testings of the presence of carbapenemases of Class A (KPC) and B (VIM, IMP, NDM) have been available.

Coris has launched the OXA-48 K-SeT, the first rapid test for the detection of the OXA-48 family carbapenemase.

 

RESIST Range will be progressively available.

Resist Range - Carbapenemase Producing Enterobacteriaceae

 

This first worldwide unique rapid test, named OXA-48 K-SeT, is aimed at the detection in 15 minutes of OXA-48-like-producing Enterobacteriacae from culture colonies.
Coris BioConcept also launched the KPC K-SeT kit whose aim is the identification of Carbapenemase KPC in bacteria culture.

Contact us for more information

Want to discover more about this new kit ? Clic on the video below to see how it works !

CARBAPENEMASE IDENTIFICATION

Interested in rapid Carbapenemase identification?

Follow us at ECCMIDCMEFASMAACC

 

Launch of new respiratory products

Coris BioConcept is proud and pleased to announce the launch of three new respiratory products!

Streptococcus group A

Beta-hemolytic group A Streptococcus is one of the main bacteria responsible for upper respiratory tract infections, including sore throats, pharyngitis and scarlet fever.
Early diagnosis and antibiotic treatment of infections with group A Streptococcus help to drastically reduce the severity of symptoms and the incidence of serious complications including acute glomerulonephritis, rheumatic fever and peritonsillar abscess.

The Strep A-Strip test detects the specific antigen of group A streptococci directly from throat swab specimens.

Contact us for more scientific or technical information regarding this product.

Or visit the Streptococcus group A page.

 

Legionella pneumophila

Legionnaires’ disease is a serious pneumonia mostly (90%) caused by Legionella pneumophila which includes several serotypes with serogroup 1 accounting for over 80% of all infections.
The Legionella K-SeT is a direct antigen test to detect the Legionella pneumophila serogroup 1 antigen in urine samples.

The sensitivity and specificity are 97.6% and 100% which makes this test a prompt and suitable diagnostic tool in legionellosis diagnosis.

Contact us for more scientific or technical information regarding this product.

Or visit the Legionella pneumophila page.

 

Influenza A & B viruses

Rapid and reliable diagnosis of influenza is essential for identification of contagious patients and effective patient management.

The Coris “Influ A+B K-SeT” shows high sensitivity (90.9% type A and 91.8% type B) and specificity (100% type A et 98.1% type B).
The use of this test for diagnosis of influenza disease should enhance patient health care by enabling rapid and appropriate use of antiviral treatments and lowering inappropriate use of preventive antibiotic treatment still often prescribed by mistake.

Contact us for more scientific or technical information regarding this product.

Or visit the Influenza A & B viruses page.

 

 

 

Coris BioConcept
www.corisbio.com

HAT Sero K-SeT (Human African Trypanosomiasis) : How to use the test !

HAT Sero K-SeT

Coris BioConcept launched last year the HAT Sero K-SeT. This kit is used for the detection of the Human African Trypanosomiasis (sleeping sickness), which is a life-threatening infection particularly virulent in sub-Saharan Africa.

Due to the hard working conditions scientists may face in Africa (extreme heat and humidity), this kit was specially developed to be easily used on the field. It doesn’t require power supply or any other equipment such as refrigerators which makes of HAT Sero K-Set a robust test that can stay at room temperature.

 

Here is below a new video showing how the HAT Sero K-SeT kit should be used.

 

©clair-obscur Productions

 

Don’t hesitate to go on the HAT product page to have more information.

Or simply contact us anytime to have answers to all the questions you might have regarding this video or the product in general.

Regards,

 

HAT test to detect sleeping sickness – Market authorization in DRC !

Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study

Summary

Background

Human African trypanosomiasis (HAT) is a life-threatening infection affecting rural populations in sub-Saharan Africa.

Large-scale population screening by antibody detection with the Card Agglutination Test for Trypanosomiasis (CATT)/Trypanosoma brucei (T b) gambiense helped reduce the number of reported cases of gambiense HAT to fewer than 10 000 in 2011.

Because low case numbers lead to decreased cost-effectiveness of such active screening, we aimed to assess diagnostic accuracy of a rapid serodiagnostic test (HAT Sero-K-SeT) applicable in primary health-care centres.

Authors:

Dr Philippe Büscher PhD, Pascal Mertens PhD, Thierry Leclipteux PhD, Quentin Gilleman MSc, Diane Jacquet, Dieudonné Mumba-Ngoyi PhD, Patient Pati Pyana Vet Dr, Marleen Boelaert PhD, Veerle Lejon PhD

 

 

The whole paper is available on the following page: Human-African-Trypanosomiasis/Sciences

HAT-K-SeT_Blanc_1

New Product : GastroVir K-SeT

This GastroVir K-SeT kit was developped for simultaneuous detection of two major viruses responsible for 50 to 70% of gastroenterological diseases: Rotavirus and Adenovirus – serotypes 40/41.

The detection requires a 15 minutes run time with only a few seconds of manual handling to collect the sample with the material provided in the kit.

Besides, a multi-centre validation has been performed on 1.201 sample and let to great results: the performances of the GastroVir K-SeT kit are similar to those of the strip format with a high sensitivity (>99%) and specificity (>99%).

 

GastroVir-K-SeT_2

 

Contact us for any other information regarding this new product !

 

NEW PRODUCT ! HAT – Rapid Detection Test for Sleeping Sickness

Human African trypanosomiasis

Human African trypanosomiasis (HAT), or sleeping sickness, is a life-threatening neglected tropical infection affecting rural populations in sub-Saharan Africa. In West and Central Africa, chronic trypanosomiasis is caused by Trypanosoma brucei gambiense infection.(1) Control of the disease has been facilitated by the use of the card agglutination test for trypanosomiasis, which is particularly suited for large-scale screening of the populations at risk.(2) With the steadily decreasing prevalence of trypanosomiasis, individual rapid diagnostic tests that can be used in primary health centers, that are stable at ambient temperatures, and that are highly specific have become a research priority.(1)

We developed two rapid diagnostic tests for trypanosomiasis caused by T. brucei gambienseinfection. The HAT Sero-Strip and HAT Sero-K-SeT tests detect trypanosome-specific antibodies and are, respectively, a dipstick and a lateral-flow device for testing blood (30 μl) or plasma (15 μl); both tests provide results in 15 minutes. The tests contain variant surface glycoproteins of the T. brucei gambiense variable antigen types LiTat 1.3 and LiTat 1.5.(3)

More information about HAT product

Evaluation of the test

The tests were evaluated with the use of plasma from 198 patients with trypanosomiasis that was confirmed on parasitologic analysis and from 99 local controls with neither clinical nor serologic evidence of the disease. The specimens were collected in the Democratic Republic of Congo (4) and obtained from the World Health Organization HAT Specimen Bank (www.who.int/trypanosomiasis_african/research/en). All specimens were tested with the use of immune trypanolysis, the reference test for detecting specific antibodies against T. brucei gambiense variable antigen types LiTat 1.3 and LiTat 1.5.(5) To evaluate the applicability of these tests when blood was used, samples of reconstituted blood were prepared by adding plasma from patients with trypanosomiasis or from local controls to sedimented blood cells from a healthy donor.

Results are summarized in Table 1. As compared with the immune trypanolysis test, the HAT Sero-Strip showed excellent sensitivity, with specificity being slightly lower when plasma was tested (P=0.05). When reconstituted blood was tested, the sensitivity and specificity of the HAT Sero-Strip did not differ significantly from the sensitivity and specificity of immune trypanolysis (P>0.05 for both comparisons); for the HAT Sero-K-SeT, the sensitivity was lower than that of immune trypanolysis (P=0.01), but the specificity was not significantly different (P=0.32).

If further evaluation in the field confirms their diagnostic accuracy, we believe that the HAT Sero-K-SeT and the HAT Sero-Strip, with an estimated price of less than $2.50 each, may become valuable tools in the control of trypanosomiasis.


Büscher P.
(Institute of Tropical Medecine), Gilleman Q. (Coris BioConcept), Lejon V. (Institute of Tropical Medecine)


References
:

1. Simarro PP, Jannin J, Cattand P. Eliminating human African trypanosomiasis: where do we stand and what comes next? PLoS Med 2008;5(2):e55.

2. Magnus E, Vervoort T, Van Meirvenne N. A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T.b. gambiense trypanosomiasis. Ann Soc Belg Med Trop 1978;58:169-76.

3. Büscher P, Draelants E, Magnus E, Vervoort T, Van Meirvenne N. An experimental latex agglutination test for antibody detection in human African trypanosomiasis. Ann Soc Belg Med Trop 1991;71:267-73.

4. Amin DN, Rottenberg ME, Thomsen AR, et al. Expression and role of CXCL10 during the encephalitic stage of experimental and clinical African trypanosomiasis. J Infect Dis 2009;200: 1556-65.

5. Van Meirvenne N, Magnus E, Büscher P. Evaluation of variant specific trypanolysis tests for serodiagnosis of human infections with Trypanosoma brucei gambiense. Acta Trop 1995;60:189-99.

Categories


Home   -   Site Map   -   Privacy Policy   -   Contact   -   FAQ                   All rights reserved CorisBioconcept SPRL 1996-2012©                           www.corisbio.com

Web traffic Optimisation
UniverSem

Design, Programming & hosting
Impact communication